5-year overall survival rate for non-small cell lung cancer (NSCLC) has remained poor (Duma et al., 2019; American Cancer Society. 2021). For over a decade, the preferred treatment and standard of care for unresectable stage III NSCLC has been concurrent chemoradiation (Aupérin et al., 2010). Previous clinical trials demonstrated that concurrent chemoradiation was superior to sequential chemoradiation in terms of overall survival in patients with locally advanced NSCLC, albeit with increased acute esophageal toxicity (Aupérin et al., 2010;Mörth et al., 2014). However, this therapy is indicated primarily for patients with good performance status, and factors such as old age, co-morbidities, and poor performance status make it difficult for other patients to tolerate the toxicity of chemotherapy. For example, in a study of 31 NSCLC patients with poor performance status (PS >2) receiving platinum combination chemotherapy, those with a malnourished nutritional status according to the Glasgow Prognostic Score were unable to complete as